Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting
Author:
Publisher
Wiley
Subject
Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1746.2009.05786.x/fullpdf
Reference22 articles.
1. Anti-TNF treatment in inflammatory bowel disease;Rutgeerts;Gastroenterology,2004
2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group;Targan;N. Engl. J. Med,1997
3. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002
4. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy?;Mortimore;Intern. Med. J,2001
5. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease;Pearce;J. Gastroenterol. Hepatol,2007
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The use of therapeutic drug monitoring for early identification of vedolizumab response in Saudi Arabian patients with inflammatory bowel disease;Scientific Reports;2023-01-31
2. Influence of the Treatment Used in Inflammatory Bowel Disease on the Protease Activities;International Journal of General Medicine;2020-12
3. Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up;Biologics: Targets and Therapy;2019-11
Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up
4. Genetic prediction profile for adalimumab response in Slovenian Crohn’s disease patients;Zeitschrift für Gastroenterologie;2019-10
5. De-escalation of biological therapy in inflammatory bowel disease: Benefits and risks;South African Medical Journal;2019-09-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3